Company intelligence / Profile preview

Nascent Pharmaceuticals

California or Hawaii [conflicting reports], United Statesnascentpharmaholdings.com ↗

Ownership: Private
Development stage: Preclinical

Overview

Nascent Pharmaceuticals developed two main drug candidates—NP-50201 targeting EGFR for psoriasis and NP-50301 targeting estrogen receptors for dry eye syndromes. Both programs were discontinued after reaching early clinical stages. The company is no longer active in the pipeline databases as of January and April 2025 updates.[2][9]

Therapeutic areas: DermatologyOphthalmology
Modalities: Small moleculesHormonal therapies
Industry: Biotech

Drug pipeline

1 asset

NP-50301

Discontinued

Beyond the preview

Go deeper on Nascent Pharmaceuticals.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Nascent Pharmaceuticals.

Explore the full profile